Clinical outcome and prognosis of Waldeyer’s ring diffuse large B-cell lymphoma:an analysis of 200 patients
10.3760/cma.j.issn.1004-4221.2015.04??007
- VernacularTitle:200例原发韦氏环弥漫大 B 细胞淋巴瘤的治疗及预后
- Author:
Yonggang XU
;
Yexiong LI
;
Weihu WANG
;
Jing JIN
;
Shulian WANG
;
Yueping LIU
;
Yongwen SONG
;
Hua REN
;
Hui FANG
;
Qingfeng LIU
;
Runye WU
;
Shunan QI
;
Bo CHEN
- Publication Type:Journal Article
- Keywords:
Diffuse large B-cell lymphoma,Waldeyer ring/ chemoradiotherapy;
Prognosis
- From:
Chinese Journal of Radiation Oncology
2015;(4):382-386
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical features, treatment outcome, and prognostic factors in patients with primary Waldeyer’ s ring diffuse large B?cell lymphoma (WR?DLBCL). Methods This study included 200 patients with a confirmed diagnosis of primary WR?DLBCL admitted to our hospital from 2000 to 2013, who consisted of 50 stage I patients, 125 stage II patients, and 25 stage III?IV patients. Most patients received 4?6 cycles of CHOP or CHOP?based chemotherapy with or without involved field radiotherapy (Waldeyer′s ring+cervical lymph node region). Results The 5?year sample size was 71. The 5?year overall survival (OS), progression?free survival (PFS), and locoregional control (LRC) rates for the whole group were 78%, 72%, and 87%, respectively. In the 175 early stage patients, chemoradiotherapy resulted in significantly higher OS, PFS, and LRC than chemotherapy alone (86% vs. 70%, P= 0?? 001;84% vs. 58%, P= 0?? 000;97% vs. 66%, P= 0?? 000). Univariate analysis showed that age, tumor size, stage, lactate dehydrogenase level, and International Prognostic Index were prognostic factors for OS, PFS, and LRC ( P= 0?? 000?0?? 036), while the prognostic factors for PFS also included Eastern Cooperative Oncology Group score and cervical nodal involvement (P= 0?? 018). Multivariate analysis showed that age and stage were prognostic factors for OS and LRC (P= 0?? 003?0?? 022), and age was the prognostic factor for PFS (P= 0?? 000). Conclusions WR?DLBCL has distinct clinical features and favorable prognoses. For early stage patients, combined?modality therapy results in significantly higher OS, PFS, and LRC.
